Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Roseberry K, Le-Niculescu H, Levey D, Bhagar R, Soe K, Rogers J, Palkowitz S, Pina N, Anastasiadis W, Gill S, Kurian S, Shekhar A, Niculescu A. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2023, 28: 2894-2912. PMID: 36878964, PMCID: PMC10615756, DOI: 10.1038/s41380-023-01998-0.Peer-Reviewed Original ResearchConceptsIndependent cohortCandidate biomarkersPsychiatric subjectsPersonalized approachConvergent functional genomics approachAnxiety disordersBest overall evidenceAdverse life eventsClinical worseningGene expression signaturesBlood biomarkersAnxiety medicationClinical utilityPsychiatric disordersHigh anxiety stateSevere anxietyUntreated anxietyDecrease qualityIndividual biomarkersAddiction potentialBiomarkersTop biomarkersAnxiety statesRisk predictionExpression signatures